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Introduction 
Uveitis is a major cause of  severe visual impairment that ac-
counts for 10–15% of  all cases of  total blindness in the US, and 
one of  the major causes of  visual handicap within the working 
population worldwide[1]. The pathogenesis of  ocular inflamma-
tion is believed to involve an abnormal T-cell response to ocular 
antigens, which leads to T-cell–mediated damage to the eye [2]. 
Augmented levels of  inflammatory cytokines, specifically tumor 
necrosis factor-α (TNF-α) have been implicated in the pathogen-
esis of  various ocular inflammatory diseases. Suppressing the im-
mune response with steroids or with conventional immunosup-
pressive drugs forms the mainstay of  treatment [3]. This achieves 
disease control and prevents vision-threatening complications in 
most patients, but a significant proportion of  patients remain un-
responsive to conventional immunosuppression and with dimin-
ished quality of  life [2]. Over the last two decades, advances in 
the understanding of  the pathogenesis of  autoimmune uveitis, as 
well as improved biotechnology, have enabled the development 
of  a new class of  drugs called biologics, which provide selective 
targeting of  the immune mediators of  the inflammation cascade. 
These drugs may potentially provide more effective and less toxic 
treatment than conventional immunosuppressive agents. Biolog-
ics include a wide variety of  drugs with different mechanisms 
of  action, including monoclonal antibodies against cell surface 
markers, cytokines and their receptors, or recombinant forms of  
natural inhibitory molecules. This article summarizes the principal 
biological agents used for the treatment of  noninfectious uveitis. 
The development of  these new drugs is one of  the most revolu-
tionary advances in recent years, and the promise of  shifting para-
digms makes it an exciting time for uveitis specialists worldwide.
Tumor Necrosis Factor Alpha (TNF-α) Antago-
nists 
TNF-α is a pleiotropic cytokine expressed in a wide variety of  in-
flammatory conditions contributing to the pathogenesis and per-
petuation of  autoimmune disease. It is produced by different cell 
types and mediates its effect through two receptors, p55 (TNFR1) 
and p75 (TNFR2) [4]. During inflammation TNF-α activates T 
cells and macrophages and upregulates other proinflammatory 
cytokines. Experimental models of  uveitis have provided sub-
stantial evidence of  TNF-α’s pivotal role in mediating intraocular 
inflammation [5,6].  Several studies showed that the serum and/
or aqueous humor concentrations of  TNF-α and soluble TNF-α 
Abstract
Uveitis comprehends a wide and heterogeneous group of  intraocular inflammatory conditions potentially sight-threatening and vari-
able therapeutic strategies have been proposed. Classical treatment with steroids and conventional immunosuppressive agents is often 
used as first-step. However, a number of  patients may not respond properly or tolerate these medications with well-known side ef-
fects. Over the last two decades, advances in the understanding of  the pathogenesis of  autoimmune uveitis, as well as improved bio-
technology, have enabled the development of  a new class of  drugs called biologics, which provide selective targeting of  the immune 
mediators of  the inflammation cascade. Biologic therapies were introduced as a new option for patients with autoimmune rheumatic 
conditions refractory to conventional therapy and due to their success have posteriorly been used in ophthalmology to treat ocular 
inflammatory disorders. These new agents may potentially provide more effective and less toxic treatment than conventional therapy. 
Biologic therapies include a wide variety of  drugs with different mechanisms of  action, including monoclonal antibodies against cell 
surface markers, cytokines and their receptors, or recombinant forms of  natural inhibitory molecules. Although some results are based 
on investigations with insufficient clinical trials, the majority of  biologics indicate preferable outcomes on refractory uveitis, with 
remarkable promise to increase the possibility of  long-term remission. The development of  these new drugs is one of  the most revo-
lutionary advances in recent years, and the promise of  shifting paradigms makes it an exciting time for uveitis specialists worldwide. 
Keywords: Uveitis; Ocular Inflammation; Biologics; Cytokines; Immunomodulation
International Journal of Ophthalmology & Eye Science, 2013 © 2
Mesquida M, Adan A (2013) Biologic Therapy for Ocular Inflammatory Diseases: An Update, Int J Ophthalmol Eye Res, 01(01), 01-08.
receptors are increased in non-infectious uveitis, especially during 
periods of  higher disease activity [7-10]. In late 1990s Dick et 
al. demonstrated the benefits of  TNF-α inhibition in minimising 
the severity of  experimental autoimmune uveoretinitis [11]. Neu-
tralizing TNF-α activity results in skewed T-cell polarization with 
reduced IFNα generation, suppressed levels of  T-cell apoptosis, 
and reduced levels of  classical myeloid cell activation, resulting 
in suppressing target organ damage [5,11]. There are currently 
5 TNF antagonists approved for use in rheumatic diseases. Two 
broad strategies are used in targeting TNF: soluble receptors (i.e., 
etanercept) vs targeting antibodies (infliximab, adalimumab, goli-
mumab, certolizumab). Amongst the targeting antibodies, a dis-
tinction can be made based on the route of  administration (intra-
venous vs subcutaneous injection) and the level of  humanization 
of  the antibody structure (chimeric, humanized, or fully human). 
TNF inhibitors are the form of  biologic therapy most commonly 
employed to treat uveitis. Although there is increasing evidence 
of  their beneficial effects in the treatment of  autoimmune uvei-
tis, TNF inhibitors are not approved for such an indication, and 
therefore its use is off-label worldwide excepting infliximab for 
Behçet’s uveoretinitis in Japan.
Etanercept (Enbrel®, Amgen Inc, CA, USA and Wyeth, NJ, USA) 
is a dimeric protein composed of  soluble TNFR and a human 
IgGFc fragment. It competitively inhibits the binding of  TNF-α 
and TNF-α, thereby resulting in decreased expression of  adhe-
sion molecules responsible for leukocyte migration and reduced 
synthesis of  proinflammatory cytokines[12]. It is administered 
subcutaneously at a dose of  25-50 mg twice a week. Etanercept 
has been effective in the treatment of  several rheumatic diseases 
[12,13], although its effect in uveitis is debatable [14,15]. Foster 
et al. showed that etanercept has no significant efficacy over pla-
cebo in preventing relapses of  uveitis[14]. Moreover, etanercept 
can worsen uveitis course or even induce ocular inflammation in 
a paradoxical effect [16-19].
Infliximab (Remicade®, Centocor, PA, USA) is a chimeric mono-
clonal antibody whose mechanism of  action consists of  neutraliz-
ing membrane-bound TNF-α and soluble TNF-α and suppressing 
TNF-α production by macrophages and lymphocytes[20]. An al-
ternative inhibition mechanism of  infliximab is the promotion of  
regulatory T (Treg) cells that acquire suppressive functions in the 
periphery [21]. Infliximab is the only chimeric TNF-α antagonist, 
composed of  a mouse antigen binding (Fab) domain and a human 
Fc domain. This is the only TNF inhibitor that is given intrave-
nously.The most  frequent dosage regimen is a induction dose of  
5 mg/kg at 0, 2, 6, and every 8 weeks thereafter depending on the 
clinical response. It is approved for use in rheumatoid arthritis, 
ankylosing spondilitis, psoriasic arthritis and plaque psoriasis and 
commonly used in Crohn´s disease.
Infliximab has the largest amount of  data amongst the different 
TNF antagonists with respect to treating ocular inflammatory dis-
ease. Infliximab has been effective for a variety of  forms of  uveitis 
(Juvenile Idiopathic Arthritis (JIA)-associated uveitis, sarcoidosis, 
Birdshot, diffuse subretinal fibrosis, sympathethic ophthalmia) 
[22-27], but most of  the evidence of  the effectiveness of  inflixi-
mab in ocular inflammatory disease comes from studies on its use 
in Behcet´s disease [28-34]. Two prospective studies of  infliximab 
for refractory Behçet’s uveitis showed a significant decrease in the 
mean number of  ocular attacks compared with conventional im-
munosuppressive therapy [28,29]. Recently, Japanese investigators 
have conducted a multicenter prospective study [31] that shows 
the efficacy of  infliximab in 63 patients with refractory Behçet’s 
uveitis during the first year of  treatment. At 12 months follow-
up, uveitis improved in 92% of  patients, unchanged in 8%, and 
worsened in none. An important advantage of  infliximab therapy 
is the rapid onset of  action compared with other medications, 
causing a rapid induction of  remission. Control of  ocular inflam-
mation is frequently observed within 1 or 2 infusions, and its 
efficacy seems superior to intravenous methilprednisolone [34]. 
Rapid and successful management of  acute fundus inflammation 
in ocular Behçet’s disease is imperative to avoid vision loss due to 
permanent lesions in the retina and optic nerve. The long term 
effects of  repetitive infliximab infusions in preventing ocular re-
lapses have been evaluated in several open prospective studies. 
Long-term remission can be sustained after cessation of  therapy 
[32,35,36]. Infliximab is also efficacious in extraocular manifesta-
tions of  Behçet’s disease such as oral and genital ulcers and /or 
arthritis in the majority of  patients.
Recent reports have suggested the possibility of  intravitreal use of  
infliximab [37,38]. Markomichelakis et al. conducted a pilot study 
in which a single intravitreal injection of  infliximab (1 mg/0.05 
mL) was given to 15 patients with Behçet’s uveitis at the onset of  
a unilateral attack. A statistically significant improvement in visual 
acuity was observed as well as resolution of  intraocular inflamma-
tion signs. The authors suggest that intravitreal infliximab may be 
considered when systemic administration is not feasible or con-
traindicated. Further studies to assess the efficacy of  intravitreal 
infliximab are required.
Regarding to safety issues, infliximab is considered to be a drug 
with low toxicity, although allergic reactions are frequent during 
infusion and usually treated without consequences with antihis-
tamines and analgesics. Its combination with methotrexate is 
convenient in order to reduce the production of  anti-infliximab 
antibodies associated to multiple infusions. On the other hand, it 
has to be taken into account that infliximab, like all other TNF 
antagonists, can reactivate latent tuberculosis (TB) and other op-
portunistic infections, and thus patients should have their risk of  
TB assessed with a prior history of  exposure, chest X-ray and 
QuantiFERON assays, given that tuberculin skin test can be al-
tered by the use of  steroids and immunosuppressive medications. 
In addition, the SITE cohort study showed that patients on anti-
TNF therapies have a greater risk of  cancer and overall mortality 
[39]. However, it has been proposed that TNF antagonists do not 
actually initiate cancer, but exacerbate pre-existing cases of  unde-
tected cancer. This statement must be considered when initiating 
therapy with these agents [40].
The remaining targeting antibodies are all given through subcuta-
neous injections.
Adalimumab (Humira®, Abbott, Chicago, IL, USA) is a fully hu-
manized monoclonal antibody that inhibits TNF-α. It is admin-
istered in subcutaneous injections40 mg every 2 weeks. When 
uveitis relapses still occur despite this dose, adalimumab may 
be administered weekly until achieving control of  inflammation 
[41]. Several reports have showed the efficacy of  adalimumab in 
treating a variety of  uveitis conditions, including JIA-associated 
uveitis, sarcoidosis, Behçet’s and ankylosing spondilitis-associated 
uveitis [42-45]. Recently, Diaz-Llopis et al. conducted a prospec-
tive study of  131 patients with refractory uveitis treated with 
adalimumab [46]. This study showed statistically significant results 
regarding adalimumab efficacy in reducing anterior and vitreous 
inflammation, macular edema, immunosuppression and steroid 
loads, as well as improving visual acuity. Since adalimumab is a 
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fully humanized antibody, it may offer superior side effect profile. 
Its most frequent side effect is the development of  a self-limit-
ed cutaneous reaction at the injection site. Theoretically it has a 
lower risk of  developing allergic reactions and anti-drug antibod-
ies when comparing to infliximab. However, its effect is not as 
fast as infliximab, probably because of  the subcutaneous route 
of  administration. For this reason, we prefer using infliximab to 
induce rapid remission in the most sight-threatening and recalci-
trant cases such as active Behçet’s uveitis. Once inflammation is 
controlled, then you can maintain remission with either infliximab 
or switching to another TNF antagonist with a subcutaneous ad-
ministration, more comfortable both for the patient and for the 
physician (totally ambulatory, avoiding hospitalization).
Pediatric uveitis differs from uveitis seen in adulthood not only 
because of  the uveitis presentation and severity of  disease but 
also by a worse prognosis and age-specific problems that may oc-
cur under therapy. Adalimumab has advantages over infliximab in 
pediatric uveitis due to less infusion reactions and intolerance and 
better treatment compliance.
There are currently many clinical trials studying the efficacy and 
safety of  adalimumab in noninfectious uveitis such as the ADUR 
trial (NCT00348153), VISUAL I, II and III (NCT01148225), and 
ADJUVITE (NCT01385826).
Golimumab (Simponi® , Abbott, Chicago, IL, USA) is a fully 
human monoclonal antibody that inhibits both free and trans-
membrane TNF-α. It is injected subcutaneously, 50mg every four 
weeks. Golimumab is a recent development in TNF antagonism 
and has been recently approved for the treatment of  various 
rheumatic conditions [47]. Due to its molecular structure -a fully 
human monoclonal antibody- has a lower probability of  devel-
oping neutralizing antibodies compared to other anti-TNF, thus 
decreasing the risk of  an allergic infusion reaction and any loss 
of  efficacy. Although fully human, resistance to golimumab may 
potentially develop as well [47]. Other advantages of  golimumab 
over other TNF antagonists include the reduced dosing schedule, 
being a monthly subcutaneous self-administration. Recently, three 
papers have been published regarding golimumab use in uveitis 
[48-50], showing its efficacy in retinal vasculitis, JIA-associated 
uveitis, and Behçet’s disease. Further studies with longer follow-
up to evaluate the long-term efficacy and safety of  golimumab in 
a larger number of  uveitis patients are warranted.
Certolizumab (Cimzia®) consists only in the pegilated humanized 
Fab portion of  a monoclonal antibody directed against TNF-α. 
Because its antibody structure lacks a constant region or Fc por-
tion, there are limitations in certolizumab’s ability to fix comple-
ment or recruit antibody-dependent cell-mediated cytotoxicity 
[51]. Certolizumab has been approved for in Crohn’s disease and 
rheumatoid arthritis in people who did not respond to standard 
therapy [52]. Certolizumab is dosed 400 mg subcutaneously 4 
weeks after 3 dose-loading spaced every 2 weeks. Currently there 
are no studies demonstrating the efficacy of  this drug in non-
infectious uveitis.
Acquired resistance to TNF antagonists may occur in the long 
term. In cases of  refractory uveitis with loss of  initial clinical re-
sponse to one biological agent (secondary failure), switching to 
another agent can restore control of  intraocular inflammation. In 
addition, switching helps controlling systemic symptoms and al-
lows ease of  administration. Why patients should respond to one 
biologic agent and not another, despite similar mechanisms of  
action, remains unexplained. Various possible hypotheses include 
differential bioavailability of  these drugs and the development of  
anti-drug antibodies [53,54].
Interferons
Interferons (IFN) are a group of  cytokines that include type I 
IFN (IFNα and IFNα, produced mainly by antigen-presenting 
cells) and type II (IFNα), produced by T cells and NK cells. IFNs, 
are thought to have an important role linking the innate with the 
adaptive immune system [55]. IFN-α has immunoregulatory and 
mmunosuppressive effects [56] and has been shown to be ben-
eficial in the treatment of  patients with uveitis [57-59]. Currently 
there are two types of  different human recombinant IFNα that 
are commercially available: non-pegylated and pegylated. The first 
class includes IFN-α2a (Roferon-A®) and IFNα-2b (IntronA®). 
Pegylated ones are Peginterferon-α2a (Pegasys®) and IFNα-2b 
(ViraferonPeg®).  Pegylation increases the size and the half-life of  
the molecule to obtain higher serum concentrations. IFNα is ap-
proved for the treatment of  viral hepatitis C and B.  IFNα is given 
by subcutaneous injections. There is no consensus about the ideal 
dose and duration of  the treatment. It is usually started with high-
dose daily injections 3 x106 to 9 x 106 IU per day, with a subse-
quent taper to low dose intermittent injections (3 x 106 IU two or 
three times a week) [56]. Steroids and immunosuppressive drugs 
may antagonize the effect of  IFNα, so the standard procedure in-
cludes discontinuation of  immunosuppressive medications prior 
to start IFNα therapy or reduce its doses as much as possible. 
IFNα was the first biological agent used for the treatment of  Be-
hçet’s disease before the advent of  TNF antagonists. Due to its 
antiviral effect, IFNα was first used in the middle 1980s in Behçet 
patients who were refractory or intolerant to conventional treat-
ments, given the fact that one of  the pathogenic hypothesis of  
Behçet’s disease states that it may be triggered by a viral infection 
[59]. Kötter et al. reviewed 338 BD patients treated with IFNα, 
182 of  them for acute uveitis [60]. This study showed that about 
94% of  the patients reached complete remission (disappearance 
of  all symptoms) or at least partial remission (a >50% decrease 
in number, severity, duration or frequency of  lesions or scores) 
of  ocular Behçet’s disease within 2-4 weeks. In addition, IFNα 
may lead to stable remission after discontinuation of  treatment. 
In Behçet patients, after a mean treatment duration of  15 months, 
long-term remission could be maintained in 56% of  patients af-
ter discontinuation of  IFNα therapy [61]. Outside ocular BD, 
IFNα has proved to be an effective treatment for other uveitis 
such as sympathetic ophthalmia, Vogt-Koyanagi-Harada disease, 
Birdshot retinochoroidopathy, and serpiginous choroiditis[56,58]. 
Recently, Butler et al evaluated the efficacy of  IFN-α2b in the 
treatment of  refractory, uveitic cystoid macular edema in 4 pa-
tients who failed therapy with locally injected corticosteroids, and 
found that treatment with systemic IFN-α2b produced dramatic 
improvement in central macular thickness and visual acuity [62] 
Another potential advantage of  IFN-αtherapy is that, unlike other 
immunosuppressants and biologics, does not increase the risk of  
opportunistic infections and is not carcinogenic. However, side 
effects are almost universal and some of  them can be fairly dan-
gerous, becoming the main limiting factors of  IFNα use [63]. Flu-
like syndrome, consisting of  fever, fatigue and headache occur 
in 100% of  patients during the first weeks of  therapy, although 
rarely are severe enough to discontinue therapy. Other serious 
side effects include hematological toxicity, alopecia, elevated liver 
enzymes, bowel dysfunction, and injection site ulcers. Psychiatric 
disorders such as depression, anxiety, and psychoses, reported in 
4 to 7.5% of  patients, can lead to suicide and thus are limiting 
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factors for the use of  IFN [63]. Development of  systemic auto-
immune diseases such as sarcoidosis or lupus induced by IFN has 
also been reported [63].
IL-1β Antagonists
Interleukin-1 beta (IL-1β) is a pro-inflammatory cytokine secreted 
by a wide variety of  cell types. It is a key initiator and mediator of  
the inflammatory cascade and a pivotal cytokine in the inflamma-
some: IL-1β acts as a messenger to upregulate the innate immune 
system’s response to infection, injury, and stress [64]. IL-1β ex-
erts its effects through interleukin-1 receptor type I (IL-1RI) and 
interleukin-1 receptor accessory protein (IL-1RAcP), which to-
gether form a heterotrimeric signaling-competent complex. IL-1β 
signalling induces cells to express additional cytokines (including 
IL-1β) as well as chemokines and other pro-inflammatory mol-
ecules. Elevated levels of  IL-1β play a major role in many autoin-
flammatory and autoimmune diseases [64]. For instance, Behçet’s 
disease has many clinical findings overlapping with those of  au-
toinflammatory disorders, and circulating monocytes of  patients 
with Behçet’s produce large amounts of  IL-1β [65].
Targeting IL-1 began in 1993 with the introduction of  Anakinra 
(Kineret®), a recombinant form of  the naturally occurring IL-1 
receptor antagonist (IL-1Ra), which blocks the activity of  both 
IL-1α and IL-1β. It is administered with an adult dose of  100 
mg daily by subcutaneous injection. It has been used to treat a 
wide variety of  autoinflammatory conditions, including chronic 
infantile neurological cutaneous articular syndrome (CINCA)-
associated uveitis refractory to anti-TNF therapy, confirming the 
success in the preclinical experimental autoimmune uveitis model 
in mice [66]. Serious infections such as pneumonia and infectious 
cellulitis seem more frequent with anakinra, although there is no 
increased risk of  tuberculosis.
Canakinumab (ACZ885) is a novel fully human IL-1β blocking 
antibody. It binds IL-1β, inhibiting its binding to IL-1 receptors 
I and II. Intravenously or subcutaneously infused, it neutralizes 
the bioactivity of  human IL-1β, which is involved in several in-
flammatory disorders [67]. Canakinumab has promising clinical 
safety and pharmacokinetic properties, and demonstrated poten-
tial for the treatment of  cryopyrin-associated periodic syndromes 
(CAPS) and possibly for other complex inflammatory diseases, 
such as rheumatoid arthritis, juvenile idiopathic arthritis, and ocu-
lar inflammatory diseases [68,69]. Early clinical trials have estab-
lished the administration of  canakinumab every 2 weeks to be 
safe and effective, offering a considerable advantage over anak-
inra, which must be injected daily and is often poorly tolerated by 
patients. Two recent reports showed the efficacy of  canakinumab 
in Behçet’s uveitis refractory to TNF antagonists[70,71].
Gevokizumab (XOMA 052) is a recombinant, partially human-
ized monoclonal antibody that binds IL-1β, reduces affinity to 
IL-1RI, leaving intact the affinity for IL-RII. It is a modulating an-
tibody that does not block the assembly of  IL-1β signalling com-
plex. It down-regulates IL-1β activity in cytokine release assays. It 
has a circulating half-life of  approximately 25 days, allowing once 
monthly dosing [72]. Gül et al. have recently conducted an open-
label pilot study to evaluate safety, clinical/biological activity and 
pharmacokinetics of  gevokizumab in 7 BD patients with acute 
intraocular inflammation resistant to immunosuppressive treat-
ment[73]. Gevokizumab 0.3 mg/kg was administered in a unique 
intravenous injection in all patients at day 0, followed by a second 
infusion in 5 patients who relapsed between days 49 and 95 of  
the study. Immunosuppressive therapies were suspended before 
entering the study. Relapses occurred when drug serum level felt 
below 2 μg/ml. Following the second infusion all patients re-
mained attack free without the need for any other medication for 
a median of  115 days. The authors reported no treatment-related 
adverse events. Limitations of  this study include its open-label 
design, the small number of  patients, the lack of  assessments of  
the extraocular manifestations, and the short follow-up. There are 
two ongoing phase III clinical trials studying the safety and effi-
cacy of  gevokizumab in noninfectious uveitis (EyeguardTM-A and 
–C) which are currently recruiting.
IL-2 Receptor Antagonism
IL-2 is an essential cytokine in the activation of  T-lymphocytes. 
The IL-2 receptor (IL2R) system plays a central role in the in-
duction of  immune responses via activated T and B-lymphocytes, 
observed both in uveitis animal models and on the surface of  hu-
man cells in patients with uveitis. Daclizumab (Zenapax®) is a hu-
manized monoclonal antibody directed against the CD25 subunit 
of  the IL2R, which is present on activated T cells. It was first ap-
proved by the FDA in 1997 for the prevention of  allograft rejec-
tion [74].  Daclizumab has demonstrated promise in the treatment 
of  childhood uveitis [75] and non- infectious intermediate and 
posterior uveitis [76,77], being particularly effective for Birdshot 
retinochroidopathy. Typically it is dosed 1-4mg/kg intravenous-
ly every 2 weeks. Unfortunately, its manufacturer withdrew this 
promising medication from the market in January 2010.
IL-6 Receptor Antagonism
Tocilizumab (Actemra®) is a humanized monoclonal antibody 
that blocks the IL-6 receptor. IL-6 is a pleiotropic, proinflamma-
tory cytokine mainly produced by T cells and monocytes/mac-
rophages, inducing proliferation and differentiation of  T cells as 
well as the terminal differentiation of  B cells. Serum levels of  
IL-6 are significantly elevated in patients with active noninfectious 
uveitis and decrease during remission [78,79]. In addition, elevat-
ed intraocular levels of  IL-6 were observed in patients with active 
intermediate or posterior uveitis and probably play an import role 
in uveitis and macular edema pathogenesis[80,81]. Tocilizumab is 
approved for the treatment of  rheumatoid arthritis and is dosed 
4-8mg/kg, given in intravenous infusion every 4 weeks. The ef-
fectiveness of  tocilizumab in uveitis has been reported in a few 
small case series so far. Muselier et al. found tocilizumab to be 
effective in two refractory uveitis cases[82]. Tappeiner reported 3 
patients with refractory uveitis associated with juvenile idiopathic 
arthritis[83]. Effectiveness of  tocilizumab treatment in Behçet’s 
uveitis has also been reported [84]. Our group recently reported 
two papers studying the efficacy of  tocilizumab infusions in uvei-
tis cases with severe cystoid macular edema refractory to systemic 
and local treatments [85,86]. It is usually very well tolerated and 
has a good safety profile. Given that IL-6 blockade does not af-
fect granulomatous inflammation, tuberculosis does not pose a 
safety issue. There are currently 3 ongoing clinical trials to study 
the efficacy of  tocilizumab in patients with non-infectious uveitis 
(the STOP-uveitis study, NCT01717170), juvenile idiopathic ar-
thritis associated uveitis (NCT01603355), and Behçet’s syndrome 
(NCT01693653).
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Anti-CD20
Although much attention gets focused to the cellular arm of  the 
adaptive immune system, the humoral arm certainly plays a role 
in many autoimmune diseases. Rituximab is a chimeric mono-
clonal antibody that binds specifically to the B lymphocyte anti-
genCD20 –present only in mature B cells-, inducing B cell death 
by apoptosis. Rituximab (Mabthera®/Rituxan®) was a revolution 
in the treatment of  B-cell lymphoma and has shown efficacy in 
many autoimmune diseases with circulating autoantibodies such 
as rheumatoid arthritis, systemic lupus erythematosus, Wegener’s 
and anti-neutrophil cytoplasmic antibody-associated vasculitis 
[86,87]. With respect to ocular disease, it is especially useful in 
masquerade syndrome due to intraocular lymphomas [88]. Ritux-
imab has also been used to treat ocular cicatricial pemphigoid, 
noninfectious scleritis, peripheral ulcerative keratitis [89], and sev-
eral cases of  refractory uveitis [90]. Rituximab is given intrave-
nously 375mg/m2 surface area usually every 2 weeks. Previous 
intravenous administration of  corticosteroids is recommended to 
prevent allergic reactions. Side effects may appear during the first 
infusion, such as fever, rash, respiratory symptoms and hyperten-
sion. Increased risk of  severe infections is one of  its major safety 
issues. The administration of  rituximab is followed by a transient 
depletion of  CD20 positive B cells that may last 6-9 months, 
therefore B cell counts should be monitored.
T-Cell Co-Stimulation Inhibition
Abatacept (Orencia®) is a fusion protein formed by a ligand-bind-
ing domain of  the cytotoxic T-lymphocyte associated antigen-4 
(CTLA-4) and a fragment of  human immunoglobulin. It induces 
a blockade of  the interaction between the T-cell co-stimulatory 
receptor CD28 and CD80/CD86 expressed on antigen present-
ing cells, thus inhibiting the co-stimulation and the activation of  
T lymphocytes [91]. It is approved for the treatment of  refractory 
rheumatoid arthritis. There is emerging data demonstrating effi-
cacy in the setting of  recalcitrant Juvenile Idiopathic Arthritis- as-
sociated uveitis that has failed traditional immune modulation or 
TNF Inhibitors [92]. It is administered with a 30-minutes slow 
intravenous infusion, given every 2 weeks for the first 3 doses and 
then every 4 weeks. It is dosed according to the weight of  the pa-
tient: 500 mg for patient weight<60kg, 750mg for patient weight 
60-100kg, 1000 mg for patient weight>100kg. Subcutaneous 
abatacept formulation is now available in some countries, with 
a similar long-term efficacy to the intravenous formulation and a 
lower immunogenicity [93]. The most relevant but infrequent ad-
verse events related to abatacept are pneumonia, lymphoma and 
breast cancer. It is currently under investigation in phase II trials 
for the treatment of  uveitis (NCT01279954).
Other Emerging Therapies
Fingolimod (FTY720) is a sphingosine-1-phosphate receptor 
modulator and the first an FDA-approved oral drug for the treat-
ment of  multiple sclerosis. Fingolimod prevents T-cell migration 
to inflammatory sites by decreasing expression of  the sphingo-
sine-1 phosphate receptor normally required for egress from sec-
ondary lymphoid tissue. In murine models, fingolimod reduces 
ocular infiltration within hours of  administration and suppresses 
clinicopathologic expression of  experimental autoimmune uveo-
retinitis [94]. These results support a strong therapeutic potential 
for fingolimod as a treatment of  ocular immune-mediated inflam-
mation and may be an effective agent for an acute rescue therapy 
for sight-threatening intraocular inflammation [95]. Two recent 
clinical trials (TRANSFORMS and FREEDOMS) demonstrated 
a significant reduction in the relapse rate of  patients with mul-
tiple scleroses when compared to interferon beta and placebo 
[95]. However, macular edema was a prominent adverse event, 
observed in 0.5% of  patients treated with fingolimod. A recent 
study conducted by Zarbin et al. observed 19 cases with macu-
lar edema among 2615 patients receiving fingolimod for multi-
ple sclerosis [95]. Fingolimod-associated macular edema tends to 
appear within 3-4 months of  treatment initiation and it is more 
prevalent in patients with a history of  uveitis. In most cases, mac-
ular edema resolves after discontinuing the drug [95]. There is 
currently a phase II clinical trial to study the safety, tolerability, 
and efficacy of  FTY720 in patients with noninfectious uveitis 
(NCT01791192) sponsored by Novartis.
Secukinumab is a fully human monoclonal antibody for targeted 
IL-17A, which is recognized as one of  the principal proinflamma-
tory cytokines in immune-mediated inflammatory diseases. High-
er levels of  IL-17A have been found in the peripheral blood of  
patients with uveitis and other systemic immune-mediated con-
ditions, such as Vogt–Koyanagi–Harada syndrome and Behçet’s 
disease, compared with healthy controls or affected patients with 
quiescent uveitis [96]. In 2007, Amadi-Obi et al   reported substan-
tial elevation in IL-17A expression in the serum of  patients with 
active uveitis and in animal models of  uveitis and demonstrated 
that IL-17A inhibition suppresses disease activity [97]. Dick et al. 
recently reported the findings from 3 clinical trials designed to 
explore the efficacy and safety of  different doses of  secukinumab 
versus placebo in the treatment of  noninfectious uveitis [98]. The 
trials enrolled patients with Behçet’s disease with posterior uveitis 
or panuveitis (SHIELD study); patients without Behçet’s disease 
with active, noninfectious uveitis (INSURE study); and patients 
without Behçet’s disease with quiescent, noninfectious uveitis 
(ENDURE study). After completion of  the SHIELD trial, which 
showed insufficient evidence for the efficacy of  secukinumab, a 
decision was made to terminate the INSURE trial early. The EN-
DURE trial also was terminated early because the results of  a 
prespecified interim data analysis did not show sufficient evidence 
of  efficacy. However, the observed effects of  secukinumab on 
several clinical parameters may provide insights into uveitis patho-
physiology that could be useful for guiding future approaches to 
treatment.
Discussion
Targeted immune modulators work by selectively blocking mech-
anisms involved in the inflammatory and immune response. The 
advancement of  our understanding immunologic mechanisms 
behind autoimmune and in particular ocular inflammatory dis-
eases has begun to yield many new and diverse therapies that 
hold great promise for immune modulation in the years to come. 
Among the studies quoted in this paper in support or against a 
particular drug, most are retrospective reviews, small studies that 
have no standard definition of  success. In addition there is also 
a strong heterogeneity of  the study variables. Another limita-
tion is the variability of  the uveitis etiologies among the patients 
included in most of  the studies. The first and foremost issue is 
how do biologics really work in uveitis? For example, peripheral 
monocytes taken from patients with active ocular Behcet’s dis-
ease are known to produce greater amounts of  TNF-α compared 
with patients with Behcet’s disease and quiescent eyes or normal 
controls. There is evidence to support the role of  TNF-α as a 
central proinflammatory cytokine contributing to the inflamma-
tory cascade that ultimately leads to tissue destruction in uveitis. 
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Unfortunately, the biological basis for therapy is less certain with 
other drugs. Furthermore, although biologic agents being used in 
patients with uveitis have first been tested in rheumatologic dis-
ease, not all agents that are effective in systemic disease are effec-
tive in the eye. As we previously mentioned, etanercept works well 
in rheumatoid arthritis but has less efficacy in uveitis and has even 
been reported to trigger de novo ocular inflammation in some 
patients being treated for their systemic disease. The reasons for 
differential efficacy between organs are poorly understood.
We considerer infliximab and adalimumab as similar treatment 
options. They share a similar action profile but different routes 
of  administration, immunogenic potential and therefore reason 
for using one or another should be related to nonclinical issues 
associated with the patient. Adalimumab appears to be effective 
and safe for treatment of  refractory JIA-related uveitis, with a 
better performance in the medium-term period and it is more 
efficacious than infliximab in maintaining remission of  chronic 
childhood uveitis.
An important issue regarding the use of  TNF inhibitors is if  
this therapy could be discontinued at any time in those patients 
achieving control of  their uveitis. Some included studies reflect 
that this option may be possible, although most of  the patients 
in these studies were on immunomodulatory drugs at the time in 
which anti-TNF therapy was discontinued. The measurement of  
serum levels of  TNF antagonists and /or antibodies against these 
agents, which may explain a possible tachyphilactic phenomenon, 
seem to be a reasonable work-up in the future management of  
patients treated with TNF antagonists. These rates of  adverse 
events are higher than those reported in shorter-term retrospec-
tive studies. Clearly, there are real related to biologic therapies 
about which both the physician and the patient need to be fully 
informed. Moreover, because of  the high cost of  biologic agents, 
whether we can actually use them unfortunately does not only 
depend on good evidence. The use of  new and expensive medi-
cal therapies such as biologics is increasingly being controlled by 
health insurance corporations and healthcare regulatory agencies. 
Although options are many and diverse, further interventional 
and longitudinal studies must be done to clarify which medi-
cations impact which diseases.  Due to the chronicity of  most 
noninfectious uveitis and the unpredictability of  remissions and 
exacerbations of  the inflammatory reactions, there is a need for 
masked evaluations, with long follow-up data, and larger num-
bers of  patients for adequate and unbiased testing of  the available 
novel biologic drugs. 
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